What drug class is KRYSTEXXA?

Krystexxa may be used alone or with other medications. Krystexxa belongs to a class of drugs called Enzymes, Oncology; Rheumatologics, Other. It is not known if Krystexxa is safe and effective in children younger than 18 years of age.

What company originally developed KRYSTEXXA?

Originally developed by Savient Pharmaceuticals, Krystexxa was taken on by Horizon Pharma in 2015. Since then, the company has seen a 40-50% growth in patients over the last year. Gout can be a debilitating disease characterized by recurrent attacks of tender, hot and swollen joints.

What is the brand name for KRYSTEXXA?

Pegloticase (trade name Krystexxa) is a medication for the treatment of severe, treatment-refractory, chronic gout. It is a third line treatment in those in whom other treatments are not tolerated. The drug is administered by infusion intravenously.

Is KRYSTEXXA over the counter?

KRYSTEXXA® (pegloticase) is a prescription medicine used in adults to help reduce the signs and symptoms of gout that are not controlled by other treatments.

Is KRYSTEXXA an orphan drug?

KRYSTEXXA was granted an Orphan Drug designation by the FDA in 2001 that the Company expects will provide the drug seven years of orphan drug market exclusivity.

Is KRYSTEXXA a biologic?

KRYSTEXXA is a biologic treatment, which means it’s made from a living source. Biologics are at the forefront of medical advances and can treat the causes of diseases rather than the symptoms.

What does KRYSTEXXA cost?

Krystexxa costs about $5,000 per month.

When does KRYSTEXXA patent expire?

Krystexxa’s orphan drug exclusivity will expire in February 2018, however, although its biologic exclusivity will last until 2022. The drug has patent protection that will last until 2027, and so the company plans to fuel the drug’s growth by increasing promotion and expanding its clinical profile.